Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.
Up to 20% weight loss at 48 weeks from an amylin-selective agonist alone — Lilly's answer to CagriSema without the GLP-1.
Also known as: LY3841136 · AT53786
Part of the Metabolic & GLP-1 peptides cluster
Overview
Eloralintide (LY3841136) is an investigational once-weekly amylin analogue from Eli Lilly that preferentially activates the amylin 1 receptor (12-fold over the calcitonin receptor). In a 48-week phase 2 trial it produced dose-dependent weight loss of 9% to 20% versus 0.4% with placebo, and a phase 3 programme began in 2025–2026.
Source & context
Biological / chemical source: Synthetic engineered amylin analogue
Primary research or clinical context: Investigational (Eli Lilly) — phase 3 programme in obesity, obesity with type 2 diabetes, sleep apnoea, osteoarthritis pain and weight maintenance
What eloralintide is
Eloralintide (LY3841136) is a novel, selective amylin receptor agonist in development by Eli Lilly for weight management, dosed once weekly by subcutaneous injection (Billings et al., Lancet 2025; Bhattachar et al., Diabetes, Obesity and Metabolism 2026). Its molecular formula is C201H319N49O65S2 with a mass of about 4,526 Da (PubChem CID 175663130); the residue-level sequence is not deposited in the IUPHAR database, so no chip display is shown here.
Mechanism: amylin-receptor selectivity
In vitro, eloralintide preferentially activated the human amylin 1 receptor, 12-fold over the calcitonin receptor and 11-fold over AMY3R, whereas in rats both AMY1R and AMY3R were activated more potently than CTR. Compared with cagrilintide, a non-selective amylin receptor agonist, it induced significantly less conditioned taste avoidance in lean rats — a preclinical proxy for nausea — and dose-dependently reduced food intake and body weight, mainly through fat loss, in diet-induced obese rats (Briere et al., Molecular Metabolism 2025). Amylin receptors are complexes of the calcitonin receptor with receptor-activity-modifying proteins; the amylin profile on this site explains the family.
Phase 1
In the single-ascending-dose study in 48 healthy participants (0.04–12 mg), adverse events were mostly mild, with four gastrointestinal events in two participants; single doses of 4 or 12 mg produced week-4 weight changes of −2.5% and −4.4% versus +0.6% with placebo (Briere et al., 2025). In the 12-week multiple-ascending-dose study of 100 participants with obesity or overweight, exposure was dose-proportional, the most common adverse events were decreased appetite (19%), headache (12%) and fatigue (11%), gastrointestinal events were infrequent (diarrhoea 10%, nausea 8%, vomiting 4%), and weight fell by 2.6% to 11.3% across dose groups (Bhattachar et al., 2026).
Phase 2: 48 weeks
A phase 2 trial at 46 US centres randomised 263 adults with obesity or overweight and at least one weight-related comorbidity, without type 2 diabetes (mean BMI 39.1), to once-weekly eloralintide 1, 3, 6 or 9 mg, two escalation schemes (6–9 mg, 3–9 mg) or placebo. Mean weight change at 48 weeks was −9% (1 mg), −12% (3 mg), −18% (6 mg), −20% (9 mg), −20% (6–9 mg) and −16% (3–9 mg) versus −0.4% with placebo. Nausea ranged from 11% (1 mg) to 64% (6 mg) and 33% (9 mg) versus 14% on placebo; fatigue from 0% to 46% versus 12% (Billings et al., Lancet 2025).
| Arm | Weight change | Nausea | Fatigue |
|---|---|---|---|
| Placebo (n=53) | −0.4% | 14% | 12% |
| 1 mg | −9% | 11% | 0% |
| 3 mg | −12% | 13% | 13% |
| 6 mg | −18% | 64% | 29% |
| 9 mg | −20% | 33% | 43% |
| 6–9 mg escalation | −20% | 54% | 46% |
| 3–9 mg escalation | −16% | 25% | 21% |
Phase 3 programme
ClinicalTrials.gov lists 17 studies as of September 2026, with phase 3 trials recruiting in obesity or overweight without diabetes (NCT07321886), with type 2 diabetes (NCT07282600), with obstructive sleep apnoea (NCT07369011), with knee osteoarthritis pain (NCT07353931) and in people with persistent obesity after treatment with a weight-loss medication (NCT07392190), plus a phase 2 trial of eloralintide alone or combined with the incretin macupatide (LY3532226) (NCT07215559).
Eloralintide vs cagrilintide, CagriSema and petrelintide
Cagrilintide alone produced up to 10.8% weight loss at 26 weeks in phase 2 and 20.4% at 68 weeks when combined with semaglutide; eloralintide reached 20% at 48 weeks as a single agent, with a tolerability profile its developers attribute to amylin-receptor selectivity. Petrelintide is a third long-acting amylin analogue with a roughly 10-day half-life. Trials differ in population and duration, and a 2026 network meta-analysis attempts a formal comparison (Kamrul-Hasan et al., Endocrinology, Diabetes & Metabolism 2026).
Status and what this page is not
Eloralintide is investigational and not approved anywhere as of September 2026. Nothing sold online under the name corresponds to a verified product; this profile is educational and not guidance on obtaining or using it.
Structure & chemistry
Molecular identity & reference confidence
Source-supported reference
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- Eloralintide (source record; form not independently established)
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
- PubChem molecular record · 2026-10-01
- Molecular formula
- C201H319N49O65S2
- Average reference mass
- ≈ 4,526
- Plasma half-life
- Pharmacokinetics support once-weekly subcutaneous dosing; exposure dose-proportional at steady state
- Receptors
- Amylin receptors, AMY1R-preferring: 12-fold selectivity over the calcitonin receptor and 11-fold over AMY3R in human cell assays
- Status
- Investigational: phase 3 (obesity, type 2 diabetes, obstructive sleep apnoea, knee osteoarthritis pain, weight maintenance); not approved as of September 2026
- PubChem CID: 175663130
- CAS RN: 2883634-40-8
Chemistry values: curated profile, PubChem · fetched 2026-10-01.
Clinical development snapshot
ClinicalTrials.gov lists 18 registered studies with “Eloralintide” as an intervention (snapshot 2026-10-01). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT07701083 | A Study of Eloralintide (LY3841136) in Healthy Participants | Phase 1 | active not recruiting | 2026-09-29 |
| NCT07321886 | A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes | Phase 3 | recruiting | 2026-09-22 |
| NCT07392190 | A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incr | Phase 3 | recruiting | 2026-09-22 |
| NCT07369011 | A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight | Phase 3 | recruiting | 2026-09-22 |
| NCT07589608 | A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult P | Phase 2 | recruiting | 2026-09-22 |
| NCT07353931 | Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or O | Phase 3 | recruiting | 2026-09-22 |
Eloralintide — reconstitution calculator
Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.
Reference form: Eloralintide (source record; form not independently established)Average reference mass: 4,526 Da
Enter an amount to see the volume it corresponds to.
Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.
Change log
Dated observations from the data pipeline (registry flags, trial footprints, identifiers) and editorial reviews of this profile.
- Trials1 registered study added on ClinicalTrials.gov (now 18).
- IdentifiersCross-linked to PubChem CID 175663130.
- TrialsClinicalTrials.gov snapshot added: 17 registered studies, highest phase 3.
- EditorialProfile content reviewed and updated by the editorial team.
FAQ about Eloralintide
What is Eloralintide?+
Eloralintide (LY3841136) is an investigational once-weekly amylin analogue from Eli Lilly that preferentially activates the amylin 1 receptor (12-fold over the calcitonin receptor). In a 48-week phase 2 trial it produced dose-dependent weight loss of 9% to 20% versus 0.4% with placebo, and a phase 3 programme began in 2025–2026.
What Canadian product status is recorded for Eloralintide?+
Canadian product status for Eloralintide has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of Eloralintide?+
Eloralintide is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.
What is eloralintide?+
LY3841136, an investigational once-weekly amylin analogue from Eli Lilly that selectively activates the amylin 1 receptor. It is in phase 3 trials for obesity.
How much weight loss did eloralintide produce?+
In a 48-week phase 2 trial, −9% to −20% depending on dose versus −0.4% with placebo; the 9 mg arm reached −20%.
Is eloralintide a GLP-1?+
No. It is an amylin receptor agonist, a different hormone pathway; it does not activate the GLP-1 receptor.
Eloralintide vs cagrilintide — what is the difference?+
Both are long-acting amylin analogues; eloralintide is selective for the amylin 1 receptor, whereas cagrilintide is a non-selective amylin/calcitonin receptor agonist and is developed in combination with semaglutide.
Related peptides
References & further reading
- 1.Billings et al. (2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet
- 2.Briere et al. (2025). Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism
- 3.Bhattachar et al. (2026). Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, Obesity and Metabolism
- 4.Kamrul-Hasan et al. (2026). Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis. Endocrinology, Diabetes & Metabolism
- 5.Fischer & Borner (2026). Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs. Pharmacological Research
- 6.PubChem — compound summary for Eloralintide (CID 175663130)